Overall prognostic impact of C-reactive protein level in patients with metastatic renal cell carcinoma treated with sorafenib.

Abstract:

:C-reactive protein (CRP) is an independent prognostic factor for renal cell carcinoma (RCC). The aim of the present study was to investigate the overall prognostic impact of CRP in patients with metastatic RCC treated with sorafenib. Between April 2008 and December 2014, 40 consecutive patients with metastatic RCC were treated with sorafenib at our institution. The patients were divided into two cohorts according to the pretreatment CRP level: (i) a normal CRP cohort (≤0.30 mg/dl) and (ii) an elevated CRP cohort (>0.30 mg/dl). Kaplan-Meier overall survival analysis was carried out. The effects of selected variables on survival were assessed by multivariate regression using the Cox proportional hazards model. The normal CRP cohort included 16 patients (40.0%) and the elevated CRP cohort included 24 patients (60.0%). The normal CRP cohort showed significantly longer overall survival than the elevated CRP cohort (median, 52.0 vs. 17.0 months; P=0.0072). On multivariate analysis, normal CRP predicted longer overall survival (hazard ratio, 0.367; 95% confidence interval, 0.147-0.914; P=0.0313). Pretreatment normal CRP predicted better overall survival in patients with metastatic RCC treated with sorafenib and CRP level may be a useful biomarker for predicting overall survival of patients treated with sorafenib.

journal_name

Anticancer Drugs

journal_title

Anti-cancer drugs

authors

Fujita T,Nishi M,Tabata K,Matsumoto K,Yoshida K,Iwamura M

doi

10.1097/CAD.0000000000000417

subject

Has Abstract

pub_date

2016-11-01 00:00:00

pages

1028-32

issue

10

eissn

0959-4973

issn

1473-5741

journal_volume

27

pub_type

杂志文章
  • Cellular cytotoxicity and in-vivo biodistribution of docetaxel poly(lactide-co-glycolide) nanoparticles.

    abstract::Docetaxel (DTX) is one of the most effective antineoplastic drugs. However, its current clinical administration, formulated in tween80, causes serious side effects. This study is focused on preparation and evaluation of poly(lactide-co-glycolide) nanoparticles (NPs) containing DTX to remove tween80. Drug encapsulation...

    journal_title:Anti-cancer drugs

    pub_type: 杂志文章

    doi:10.1097/CAD.0b013e328331f934

    authors: Esmaeili F,Dinarvand R,Ghahremani MH,Ostad SN,Esmaily H,Atyabi F

    更新日期:2010-01-01 00:00:00

  • Evaluation of the antineoplastic activity of gallic acid in oral squamous cell carcinoma under hypoxic conditions.

    abstract::The purpose of the current study was to develop and test a theoretical model that could explain the mechanism of action of gallic acid (GA) in the oral squamous cell carcinoma context for the first time. The theoretical model was developed using bioinformatics and interaction network analysis to evaluate the effect of...

    journal_title:Anti-cancer drugs

    pub_type: 杂志文章

    doi:10.1097/CAD.0000000000000342

    authors: Guimaraes TA,Farias LC,Fraga CA,Feltenberger JD,Melo GA,Coletta RD,Souza Santos SH,de Paula AM,Guimaraes AL

    更新日期:2016-06-01 00:00:00

  • Characterization of molecular events in a series of bladder urothelial carcinoma cell lines with progressive resistance to arsenic trioxide.

    abstract::Our previous studies have shown that arsenic trioxide (As2O3), a novel anti-cancer agent, may be active against urothelial carcinomas. A series of bladder urothelial carcinoma cells with progressive As2O3 resistance were established and studied to reveal molecular events in relation to the mechanisms of resistance to ...

    journal_title:Anti-cancer drugs

    pub_type: 杂志文章

    doi:10.1097/00001813-200409000-00007

    authors: Hour TC,Huang CY,Lin CC,Chen J,Guan JY,Lee JM,Pu YS

    更新日期:2004-09-01 00:00:00

  • A phase I clinical and pharmacological study of oral 9-nitrocamptothecin, a novel water-insoluble topoisomerase I inhibitor.

    abstract::9-Nitrocamptothecin (9NC) is a water-insoluble topoisomerase I inhibitor with a broad antitumor activity in animal models. To determine the maximum tolerated oral dose (MTD), a phase I study was performed in patients with advanced cancer refractory to conventional chemotherapy. 9NC was administered orally with escalat...

    journal_title:Anti-cancer drugs

    pub_type: 临床试验,杂志文章

    doi:10.1097/00001813-199801000-00004

    authors: Verschraegen CF,Natelson EA,Giovanella BC,Kavanagh JJ,Kudelka AP,Freedman RS,Edwards CL,Ende K,Stehlin JS

    更新日期:1998-01-01 00:00:00

  • Resistance of colon cancer to 5-fluorouracil may be overcome by combination with chloroquine, an in vivo study.

    abstract::Autophagy is a complex of adaptive cellular response that enhances cancer cell survival in the face of cellular stresses such as chemotherapy. Recently, chloroquine diphosphate (CQ), a widely used antimalarial drug, has been studied as a potential inhibitor of autophagy. Here, we aimed to investigate the role of CQ in...

    journal_title:Anti-cancer drugs

    pub_type: 杂志文章

    doi:10.1097/CAD.0b013e328353f8c7

    authors: Sasaki K,Tsuno NH,Sunami E,Kawai K,Hongo K,Hiyoshi M,Kaneko M,Murono K,Tada N,Nirei T,Takahashi K,Kitayama J

    更新日期:2012-08-01 00:00:00

  • Cytotoxicity of cantharidin analogues targeting protein phosphatase 2A.

    abstract::Cantharidin is a natural toxin that possesses potent anti-tumor properties. Its clinical application, however, is limited due to severe side-effects. Its cytotoxicity is believed to be mediated by the inhibition of serine/threonine protein phosphatase 2A. In order to identify new compounds with potential clinical ther...

    journal_title:Anti-cancer drugs

    pub_type: 杂志文章

    doi:10.1097/01.cad.0000217428.90325.35

    authors: Shan HB,Cai YC,Liu Y,Zeng WN,Chen HX,Fan BT,Liu XH,Xu ZL,Wang B,Xian LJ

    更新日期:2006-09-01 00:00:00

  • Parotid gland metastasis from prostate cancer: is docetaxel still the best treatment option?

    abstract::Metastases of prostate cancer originating from the parotid gland are rare. However, this presentation raises the question of the management of visceral metastasis in castration-resistant prostate cancer. We report the case of an 87-year-old man who presented with a right painless parotid mass in the context of castrat...

    journal_title:Anti-cancer drugs

    pub_type: 杂志文章

    doi:10.1097/CAD.0000000000000188

    authors: Hélissey C,Rouanne M,Arnaud FX,Le Moulec S

    更新日期:2015-03-01 00:00:00

  • 7-Keto hybrid steroidal esters of nitrogen mustard: cytogenetic and antineoplastic effects.

    abstract::Four newly synthesized antitumor steroidal compounds were compared, on a molar basis, regarding their ability to induce sister chromatid exchanges (SCEs) and cell division delays. The concept of designing and developing these compounds (1-4) is to enhance the anticancer activity of esteric steroidal derivatives of nit...

    journal_title:Anti-cancer drugs

    pub_type: 杂志文章

    doi:10.1097/00001813-200207000-00011

    authors: Karayianni V,Papageorgiou A,Mioglou E,Iakovidou Z,Mourelatos D,Fousteris M,Koutsourea A,Arsenou E,Nikolaropoulos S

    更新日期:2002-07-01 00:00:00

  • Doxorubicin induces apoptosis in Jurkat cells by mitochondria-dependent and mitochondria-independent mechanisms under normoxic and hypoxic conditions.

    abstract::In this study, we investigated the molecular mechanism of doxorubicin (dxr)-induced cytotoxicity on Jurkat cells - a model cell of human acute lymphoblastic leukemia - under normoxic (20% O2) and hypoxic (5% O2) conditions. Using in-cell western analysis, immunofluorescence, flow cytometry analysis, and biochemical in...

    journal_title:Anti-cancer drugs

    pub_type: 杂志文章

    doi:10.1097/CAD.0000000000000223

    authors: Mendivil-Perez M,Velez-Pardo C,Jimenez-Del-Rio M

    更新日期:2015-07-01 00:00:00

  • A functionalized poly(amidoamine) nanocarrier-loading 5-fluorouracil: pH-responsive drug release and enhanced anticancer effect.

    abstract::A functionalized poly(amidoamine) (PAMAM) nanocarrier was designed and prepared to deliver anticancer drugs. The nanocarrier is a copolymer with a core-shell structure with 3.0 G PAMAM as the core and sequentially conjugated poly(2-(N,N-diethylamino)ethyl methacrylate) (pDEA) and methoxy-poly(ethylene glycol) 2000 (mP...

    journal_title:Anti-cancer drugs

    pub_type: 杂志文章

    doi:10.1097/CAD.0b013e32835920fa

    authors: Du L,Jin Y,Yang J,Wang S,Wang X

    更新日期:2013-02-01 00:00:00

  • Endometrial stromal sarcoma of the uterus.

    abstract::Uterine sarcomas are rare tumors constituting 1-3% of all uterine malignancies. These tumors are characterized by aggressive growth and by poor overall prognosis. There is much controversy concerning diagnostic criteria and the great variation in histology, as well as the role of radiotherapy and chemotherapy in the m...

    journal_title:Anti-cancer drugs

    pub_type: 杂志文章

    doi:10.1097/00001813-199102000-00004

    authors: Meden H,Meyer-Rath D,Schauer A,Kuhn W

    更新日期:1991-02-01 00:00:00

  • 9-ING-41, a small-molecule glycogen synthase kinase-3 inhibitor, is active in neuroblastoma.

    abstract::Advanced stage neuroblastoma is a very aggressive pediatric cancer with limited treatment options and a high mortality rate. Glycogen synthase kinase-3β (GSK-3β) is a potential therapeutic target in neuroblastoma. Using immunohistochemical staining, we observed positive GSK-3β expression in 67% of human neuroblastomas...

    journal_title:Anti-cancer drugs

    pub_type: 杂志文章

    doi:10.1097/CAD.0000000000000652

    authors: Ugolkov AV,Bondarenko GI,Dubrovskyi O,Berbegall AP,Navarro S,Noguera R,O'Halloran TV,Hendrix MJ,Giles FJ,Mazar AP

    更新日期:2018-09-01 00:00:00

  • Aggressive lymphoma: improving treatment outcome with rituximab.

    abstract::The standard therapy for patients with aggressive lymphoma is cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) chemotherapy, which achieves a complete response in more than 60% of patients but is curative in only about 40-50%. More aggressive and/or dose-intensified chemotherapy regimens have failed to...

    journal_title:Anti-cancer drugs

    pub_type: 杂志文章

    doi:10.1097/00001813-200211002-00007

    authors: Coiffier B,Pfreundschuh M,Stahel R,Vose J,Zinzani PL

    更新日期:2002-11-01 00:00:00

  • In vitro activity of the novel cytotoxic agent CHS 828 in childhood acute leukemia.

    abstract::CHS 828, a pyridyl cyanoguanidine, is a new drug candidate now in phase I/II trials, that has shown promising anticancer activity in experimental tumor models and primary cultures of cancer cells from patients. In this study the fluorometric microculture cytotoxicity assay was used for evaluation of CHS 828 in primary...

    journal_title:Anti-cancer drugs

    pub_type: 杂志文章

    doi:10.1097/00001813-200208000-00008

    authors: Frost BM,Lönnerholm G,Nygren P,Larsson R,Lindhagen E

    更新日期:2002-08-01 00:00:00

  • Phase II evaluation of interleukin-4 in patients with non-Hodgkin's lymphoma: a Southwest Oncology Group trial.

    abstract::We performed a phase II, Southwest Oncology Group (SWOG) clinical trial of recombinant human interleukin-4 (rhuIL-4) in patients with previously treated non-Hodgkin's lymphoma (NHL). We studied 18 eligible patients with low-grade and 21 patients with intermediate- or high-grade NHL. All patients had received prior che...

    journal_title:Anti-cancer drugs

    pub_type: 临床试验,杂志文章,多中心研究

    doi:10.1097/00001813-200010000-00004

    authors: Taylor CW,LeBlanc M,Fisher RI,Moore DF Sr,Roach RW,Elias L,Miller TP

    更新日期:2000-10-01 00:00:00

  • A phase II study of an oxaliplatin/vinorelbine/5-fluorouracil combination in patients with anthracycline-pretreated and taxane-pretreated metastatic breast cancer.

    abstract::The aim of this phase II study was to evaluate safety and efficacy of an oxaliplatin/vinorelbine/5-fluorouracil (FON) combination in anthracycline and taxane-pretreated metastatic breast cancer patients. The following treatment was given: on day 1 of a 21-day cycle, oxaliplatin 130 mg/m (2-h intravenous infusion); on ...

    journal_title:Anti-cancer drugs

    pub_type: 杂志文章

    doi:10.1097/01.cad.0000231475.77159.aa

    authors: Delozier T,Guastalla JP,Yovine A,Levy C,Chollet P,Mousseau M,Delva R,Coeffic D,Vannetzel JM,Zazzi ES,Brienza S,Cvitkovic E

    更新日期:2006-10-01 00:00:00

  • Doxycycline and other tetracyclines in the treatment of bone metastasis.

    abstract::The tetracycline family includes tetracycline, doxycycline and minocycline, all of which have been used as antibiotics effectively for decades. New uses emerged for these compounds after their effect on mitochondrial function was discovered. Cytostatic and cytotoxic activity of these compounds was shown against cell l...

    journal_title:Anti-cancer drugs

    pub_type: 杂志文章,评审

    doi:10.1097/00001813-200311000-00001

    authors: Saikali Z,Singh G

    更新日期:2003-11-01 00:00:00

  • Plasma pharmacokinetics of idarubicin and its 13-dihydro metabolite--a comparison of bolus versus 2 h infusion during a 3 day course.

    abstract::The plasma pharmacokinetics of a second generation anthracycline derivative, idarubicin (Ida), have been studied in 17 patients with acute myelocytic leukemia (AML) and high risk features. The drug (10 mg/m2) was given in a randomized cross-over design as 3 min and 2 h infusions for three consecutive days. Cytosine ar...

    journal_title:Anti-cancer drugs

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1097/00001813-199701000-00005

    authors: Eksborg S,Björkholm M,Hast R,Fagerlund E

    更新日期:1997-01-01 00:00:00

  • Baicalin inhibits human osteosarcoma cells invasion, metastasis, and anoikis resistance by suppressing the transforming growth factor-β1-induced epithelial-to-mesenchymal transition.

    abstract::The epithelial-mesenchymal transition (EMT) plays an important role in inducing cancer metastasis. Baicalin, a flavone derivative isolated from Scutellaria spp., shows a series of pharmacological and physiological activities. However, the possible role of baicalin in the EMT is unclear. In this study, we attempted to ...

    journal_title:Anti-cancer drugs

    pub_type: 杂志文章

    doi:10.1097/CAD.0000000000000495

    authors: Wang Y,Wang H,Zhou R,Zhong W,Lu S,Ma Z,Chai Y

    更新日期:2017-07-01 00:00:00

  • Inhibition of breast and ovarian carcinoma cell growth by 1,25-dihydroxyvitamin D3 combined with retinoic acid or dexamethasone.

    abstract::This study examined the growth inhibitory effects of combining 1,25-dihydroxyvitamin D3 (calcitriol) with retinoic acid or dexamethasone against cultured breast and ovarian carcinoma cells. Retinoic acid (12.5-50 nM) increased the effectiveness of calcitriol (12.5-50 nM) against MCF-7 and NIH:OVCAR3 cells, with synerg...

    journal_title:Anti-cancer drugs

    pub_type: 杂志文章

    doi:10.1097/00001813-199508000-00009

    authors: Saunders DE,Christensen C,Williams JR,Wappler NL,Lawrence WD,Malone JM,Malviya VK,Deppe G

    更新日期:1995-08-01 00:00:00

  • L-Methionine inhibits growth of human pancreatic cancer cells.

    abstract::We have previously shown that L-methionine inhibits proliferation of breast, prostate, and colon cancer cells. This study extends these findings to BXPC-3 (mutated p53) and HPAC (wild-type p53) pancreatic cancer cells and explores the reversibility of these effects. Cells were exposed to L-methionine (5 mg/ml) for 7 d...

    journal_title:Anti-cancer drugs

    pub_type: 杂志文章

    doi:10.1097/CAD.0000000000000038

    authors: Benavides MA,Bosland MC,da Silva CP,Gomes Sares CT,de Oliveira AM,Kemp R,dos Reis RB,Martins VR,Sampaio SV,Bland KI,Grizzle WE,dos Santos JS

    更新日期:2014-02-01 00:00:00

  • Decrease of CD117 expression as possible prognostic marker for recurrence in the resected specimen after imatinib treatment in patients with initially unresectable gastrointestinal stromal tumors: a clinicopathological analysis.

    abstract::Gastrointestinal stromal tumors (GIST) are the most common malignant mesenchymal tumors of the gastrointestinal tract. The principal treatment modality for primary GIST is surgery whereas for metastatic GIST, imatinib has an established role. In patients with locally advanced and metastatic GIST, the role of surgery i...

    journal_title:Anti-cancer drugs

    pub_type: 杂志文章

    doi:10.1097/CAD.0b013e32830138f9

    authors: Mearadji A,den Bakker MA,van Geel AN,Eggermont AM,Sleijfer S,Verweij J,de Wilt JH,Verhoef C

    更新日期:2008-07-01 00:00:00

  • Selective cytostatic and cytotoxic effects of glucosinolates hydrolysis products on human colon cancer cells in vitro.

    abstract::Glucosinolates hydrolysis products are attracting increasing attention since many studies have suggested that they may be involved in the anticarcinogenic property of cruciferous vegetables. In this study, we show that diindolylmethane (DIM) and sulforaphane, produced during the hydrolysis of glucobrassicin and glucor...

    journal_title:Anti-cancer drugs

    pub_type: 杂志文章

    doi:10.1097/00001813-199802000-00005

    authors: Gamet-Payrastre L,Lumeau S,Gasc N,Cassar G,Rollin P,Tulliez J

    更新日期:1998-02-01 00:00:00

  • Feasibility and toxicity of CCNU therapy in elderly patients with glioblastoma multiforme.

    abstract::In our institution, 103 glioblastoma multiforme (GBM) patients aged from 55 to 83 years were treated since November 1994 as follows. All patients underwent surgical intervention (gross total resection, n = 35; subtotal resection, n = 38; stereotactic biopsy, n = 30). Subsequently all patients were offered radiotherapy...

    journal_title:Anti-cancer drugs

    pub_type: 临床试验,杂志文章

    doi:10.1097/00001813-200302000-00007

    authors: Piribauer M,Fazeny-Dörner B,Rössler K,Ungersböck K,Czech T,Killer M,Dieckmann K,Birner P,Prayer D,Hainfellner J,Muhm M,Marosi C

    更新日期:2003-02-01 00:00:00

  • Abiraterone acetate and acute leukemia: a casual association?

    abstract::We present the case of a 70-year-old patient affected by metastatic castration-resistant prostate cancer. He underwent radical prostatectomy in 2007 and subsequent adjuvant radiotherapy and hormonal therapy for 2 years. In 2011, he developed bilateral lung metastases, and therefore he received chemotherapy (eight cycl...

    journal_title:Anti-cancer drugs

    pub_type: 杂志文章

    doi:10.1097/CAD.0000000000000988

    authors: Bolzacchini E,Patriarca C,Giordano M

    更新日期:2021-01-01 00:00:00

  • Selective delivery of etoposide to intraperitoneal tissues using a new dosage format: etoposide microcrystals suspended in oil.

    abstract::Rats received an intraperitoneal bolus injection of etoposide at 5 mg/kg of body weight in the form of an etoposide microcrystal suspension in oil (ETOP-OIL) or an aqueous etoposide solution. The tissue distribution was subsequently analyzed using high performance liquid chromatography. ETOP-OIL delivered significantl...

    journal_title:Anti-cancer drugs

    pub_type: 杂志文章

    doi:10.1097/00001813-199302000-00003

    authors: Hagiwara A,Takahashi T,Lee M,Sakakura C,Shoubayashi S,Tashima S,Yamamoto A,Muranishi S

    更新日期:1993-02-01 00:00:00

  • A retrospective comparative study of epirubicin-lipiodol emulsion and cisplatin-lipiodol suspension for use with transcatheter arterial chemoembolization for treatment of hepatocellular carcinoma.

    abstract::Transcatheter arterial chemoembolization (TACE) is widely used to treat unresectable hepatocellular carcinoma (HCC). Recently, a fine-powder formulation of cisplatin (DDP-H) was developed in Japan. We aimed to compare clinical outcomes after TACE using epirubicin or DDP-H in patients with HCC. We evaluated 202 patient...

    journal_title:Anti-cancer drugs

    pub_type: 杂志文章

    doi:10.1097/cad.0b013e328342231d

    authors: Yodono H,Matsuo K,Shinohara A

    更新日期:2011-03-01 00:00:00

  • Schlafen-11 sensitizes colorectal carcinoma cells to irinotecan.

    abstract::Schlafen-11 (SLFN11) showed a highly significant positive correlation with the response of topoisomerase inhibitors in cancer cell lines derived from prostate, lung, etc. However, this finding has not been validated in colorectal cancers (CRCs). Although irinotecan (CPT-11), a topoisomerase inhibitor, is one of the mo...

    journal_title:Anti-cancer drugs

    pub_type: 杂志文章

    doi:10.1097/CAD.0000000000000151

    authors: Tian L,Song S,Liu X,Wang Y,Xu X,Hu Y,Xu J

    更新日期:2014-11-01 00:00:00

  • Advanced breast cancer: chemotherapy phase III trials that change a standard.

    abstract::At the present time, there is not a standard regimen in upfront metastatic setting for breast cancer. A wide variety of regimens which includes anthracyclines, taxanes, gemcitabine or capecitabine are currently used, however, there is evidence to support the use of many of these drugs in early breast cancer and conseq...

    journal_title:Anti-cancer drugs

    pub_type:

    doi:10.1097/CAD.0b013e3280bad81a

    authors: Estevez LG,Tusquets I,Muñoz M,Adrover E,Rovira PS,Seguí MA,Rodríguez CA,Lescure AR,Ruiz M,Alvarez I,Mata JG

    更新日期:2007-08-01 00:00:00

  • Gemcitabine plus cisplatin chemotherapy with concurrent para-toluenesulfonamide local injection therapy for peripherally advanced nonsmall cell lung cancer larger than 3 cm in the greatest dimension.

    abstract::Para-toluenesulfonamide (PTS), active ingredient being PTS, is a new anticancer drug applied through local intratumoral injection. The aim of this phase II clinical trial was to investigate the response and toxicity of standard gemcitabine (GEM) plus cisplatin (CIS) chemotherapy with concurrent intratumoral injection ...

    journal_title:Anti-cancer drugs

    pub_type: 杂志文章

    doi:10.1097/CAD.0b013e32832fe48f

    authors: He J,Ying W,Yang H,Xu X,Shao W,Guan Y,Jiang M,Wu Y,Zhong B,Wang D,Tucker S,Zhong N

    更新日期:2009-10-01 00:00:00